-
Howson "joined" CSPC successfully "sniped" Pfizer's sunitinib patent and was invalidated!
Time of Update: 2021-05-10
In February 2021, the State Intellectual Property Office issued the "Administrative Adjudication Measures for the Early Resolution Mechanism for Pharmaceutical Patent Disputes (Draft for Comment)" which did not mention the encouragement of the first successful patent challenge and the first approved chemical generic drug applicant Matters.
-
The clinical application for ASKC852 tablets of Aosaike was approved by CDE...
Time of Update: 2021-05-10
On April 23, Osaikang declared a new drug clinical application for the first class of new drug ASKC852 tablets, which was undertaken by CDE, which is a small molecule immunomodulatory drug.
-
Hengrui Medicine's application for the listing of CDK 4/6 inhibitors has been accepted and R&D investment nearly 2...
Time of Update: 2021-05-10
On April 27, the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China announced that Hengrui Medicine's Class 1 new drug CDK 4/6 inhibitor SHR6390 tablets had submitted a new drug marketing application and was accepted.
-
27 Jiangsu pharmaceutical companies collectively collect 120 billion!
Time of Update: 2021-05-10
5 billion yuan, 6 new drugs were applied for listing, and 14 new drugs entered Phase III clinical trials; 19 varieties of Hausen were the first to be reviewed, 8 varieties were the first to be imitated, and 3 Class 1 new drugs are in phase III clinical and above; CXO leader WuXi AppTec's performance exceeds expectations, and CDMO business continues to accelerate; Simcere's differentiated R&D projects have appeared, and more than 50 innovative drug projects are under development.
-
Live broadcast preview | Promote the rational use of drugs and standardize anti-cancer treatment online kick-off meeting to be held soon
Time of Update: 2021-05-10
In order to help implement the National Health Commission's requirements for the management of anti-tumor drugs at all levels of medical institutions, ensure the rational use of drugs, and improve the level of comprehensive clinical tumor management, the public welfare project was launched.
-
2021 CSCO Guidelines Update | Key Points of Multiple Myeloma Update
Time of Update: 2021-05-09
Update key points of treatment options suitable for transplantation of newly diagnosed multiple myeloma: In the induction therapy, "Isazomib + lenalidomide + dexamethasone (2B evidence), lenalidomide + cyclophosphamide + dexamethasone (2A) Class Evidence)” was adjusted from the recommendation of level III experts to the recommendation of level II experts, with the addition of “daretuzumab + bortezomib + lenalidomide + dexamethasone (category 2) and daretuzumab + "Bortezomib + Thalidomide + Dexamethasone (Class 2)" is a level II recommendation.
-
Cell Journal: Wang Rongfu's team confirmed that a single intestinal strain can inhibit colon cancer
Time of Update: 2021-05-09
On April 23, 2021, the team of Professor Rongfu Wang from the Keck School of Medicine of the University of Southern California published a research paper entitled: Microbiota regulate innate immune signaling and protective immunity against cancer in the journal Cell Host & Microbe.
-
Interpretation of the 2021 CSCO Guidelines for Composite SCLC and Transformational SCLC Guidelines
Time of Update: 2021-05-09
The guidelines for complex small cell lung cancer recommend interpretation of the treatment of C-SCLC so far, there is still a lack of large-sample prospective randomized controlled clinical research data, most of which are small-sample retrospective analysis and case reports.
What is recommended by the compound SCLC guidelines as transforming small cell lung cancer?
-
Professor Zhang Xiaotian | CSCO Gastric Cancer Diagnosis and Treatment Guidelines 2021: An updated interpretation of non-metastatic gastric cancer
Time of Update: 2021-05-09
Some literature reports that for patients with locally advanced gastric cancer who can tolerate surgery and have good general conditions, either radical or palliative resection can bring survival benefits.
-
What is the difference between the 2020 CSCO liver cancer diagnosis and treatment guidelines and the European and American guidelines?
Time of Update: 2021-05-09
*Only for medical professionals to read and compare the 2020 version of the CSCO guideline with the European and American guidelines to understand more suitable diagnosis and treatment plans for liver cancer patients in China.
-
The PD-1 antibody purchased by GSK for US$5.1 billion was approved for listing in the U.S. and EU at the same time | Yimai Meng broke the news
Time of Update: 2021-05-09
Recent popular reports from Yimaike ★ Nanjing · Big coffee gathered in May 2021 Nucleic Acid Drug Development Forum Announcement Schedule ★ May Nanjing 2021 Nucleic Acid Drug Development Forum is abo
-
Being old and not dying is a thief!
Time of Update: 2021-05-09
A recent study by a team at Kumamoto University in Japan showed that tumor-associated fibroblasts (CAFs) in the microenvironment of gastric cancer will become the driving force of gastric cancer peritoneal metastasis in the aging state.
Therefore, the treatment of CAFs can indirectly cut off the peritoneal metastasis pathway of gastric cancer cells.
-
The 2021 CSCO guide will explain the SCLC radiotherapy part, Professor Bi Nan will show you!
Time of Update: 2021-05-09
The results showed that surgery + adjuvant chemotherapy significantly prolonged the survival benefit of lymph node-negative SCLC patients compared with concurrent radiotherapy and chemotherapy.
The pN2 with positive mediastinal lymph nodes received postoperative chemotherapy combined with adjuvant radiotherapy significantly improved the 5-year survival rate (29.
-
Innovative dual-target RNAi therapy has promising prospects, Shengnuo Pharmaceutical launches another clinical trial | Yimaimeng broke the news
Time of Update: 2021-05-09
Recent popular reports from Yimaike ★ AAV-delivered microRNA gene therapy enters clinical research Yimai Meng broke the news ★ The field of mRNA technology is blooming, how to optimize the next gener
-
Treatment of bronchopulmonary/thymus neuroendocrine tumors, interpretation of the 2021 CSCO guidelines
Time of Update: 2021-05-09
Treatment of large cell neuroendocrine tumorsLarge cell neuroendocrine tumors (LCNEC) are a type of tumor with a relatively high degree of malignancy between carcinoid and small cell lung cancer (SCLC).
-
Professor Jun Peng: How to diagnose and treat tumor chemotherapy-related thrombocytopenia
Time of Update: 2021-05-09
The results of the study showed that rhIL-11 and rhTPO had no significant difference in the number of days that the platelet levels of patients recovered to 75×109/L.
-
[Nature] Scientists from the University of Cambridge have developed a new type of anticancer drug with the potential to treat leukemia, and for the first time use the METL3 enzyme as a target against cancer
Time of Update: 2021-05-09
Inhibition of METTL3 by the small drug molecule STM2457 can block the carcinogenesis caused by the overexpression of enzymes, thereby significantly inhibiting the process of AML.
-
2021 AACR | PI Interview: Professor Li Gaofeng's wonderful comment on tislelizumab RATIONALE 303 research, Chinese wisdom shines on the international stage!
Time of Update: 2021-05-09
Compared with chemotherapy, tislelizumab alone can significantly improve the second/third-line non- The overall survival of patients with small cell lung cancer (NSCLC), and the safety is good.
-
Prof. Chunfang Hao | 2021 CSCO BC Diagnosis and Treatment Guidelines Update: Update Points and Progress of HR Positive Advanced Breast Cancer
Time of Update: 2021-05-09
Evidence-based evidence-based AI+CDK4/6 inhibitor PALOMA-2 study compared pipercillil+letrozole vs placebo+letrozole for postmenopausal ER+, HER2- advanced breast cancer patients Efficacy, the results showed that the median progression-free survival (PFS) of the piperacillil group was significantly better than that of the placebo group (30.
-
An overview of the article: 2021 CSCO Small Cell Lung Cancer Guidelines Update Key Points
Time of Update: 2021-05-09
"The ALTER1202 study update at the ASCO conference in 2020 shows that Anlotinib can significantly improve the PFS and OS of patients with relapsed SCLC within 3 months of second-line treatment.
